A tumor board puts every discipline on a hard case at one table, arguing it out before anyone commits. Everyboard brings that structure to the treating physician, for any solid tumor.
We came to it sideways. Everyboard began as a general tool for structured deliberation: several perspectives argue the same question, and their disagreements stay on the record. A clinician who ran patient cases through it asked why we didn’t turn it into a tumor board, and in 2026 we rebuilt Everyboard around that question. We live and work in central Washington, and we are starting with independent practices across the Pacific Northwest.
Why now
14,547
hematologists and medical oncologists billing Medicare in 2024
2,276
US medical oncology practices in 2022, 18% fewer than in 2015, while medical oncologists grew 14.5%
82%
of US physicians employed by hospitals or corporate entities in January 2026
Cancer care in the US is consolidating into hospitals and corporate groups.
Everyboard is built for the practices that stay physician-owned: every specialty’s written reasoning on a hard case, for any solid tumor, before the plan is set. We are starting with independent practices in the Pacific Northwest.
Co-founder and chief executive
Justin’s father died of a brain tumor, and his career began at the Leukemia & Lymphoma Society. He went on to brand marketing for REI, Eddie Bauer and evo, and in 2017 bought a backcountry adventure tourism company, which he grew and sold in 2025. He leads strategy and go-to-market at Everyboard.
Co-founder and chief technology officer
Dave has spent twenty years in systems architecture, cybersecurity and compliance, including security programs for Fortune 20 financial services, telecom and technology organizations and FedRAMP, SOC 2 Type II and ISO 27001 work. His background includes Joint Special Operations communications. He holds the CISSP and builds Everyboard's platform and its security program.
Chief clinical advisor
Michael is an Advanced Practice Provider and Teaching Associate at Fred Hutchinson Cancer Center and University of Washington Medical Center, sub-specializing in genitourinary medical oncology. For the past decade, he has cared for patients from locally advanced disease through metastatic and end-of-life settings. He is a sub-investigator on numerous Phase 1b–3 clinical trials, many of which led to FDA-approved therapies, including enfortumab vedotin and lutetium-177 PSMA, and a co-author on the associated research. He has been invited faculty at national conferences including JADPRO Live and ONS Congress. Michael reviews Everyboard's outputs and authored the protocol for its clinical evaluation.
We read every request ourselves and will get back to you within two business days.
Request access